PCS
TEVA icon

Personal CFO Solutions’s Teva Pharmaceuticals TEVA Stock Holding History

Personal CFO Solutions’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Buy
32,316
+833
+3% +$27.7K 0.16% 115
2026
Q1 		$948K Buy
31,483
+22,441
+248% +$722K 0.13% 135
2025
Q4 		$282K Buy
+9,042
New +$223K 0.04% 389
2025
Q2 		– Sell
-10,259
Closed -$158K – 509
2025
Q1 		$158K Sell
10,259
-33
-0.3% -$589 0.03% 440
2024
Q4 		$227K Sell
10,292
-188
-2% -$3.42K 0.04% 408
2024
Q3 		$189K Buy
+10,480
New +$183K 0.03% 546

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Personal CFO Solutions's TEVA Position: Q2 2026 in Review

Personal CFO Solutions increased its Teva Pharmaceuticals (TEVA) stake by 2.6% in Q2 2026, buying an estimated $27.7K and bringing the position to 32,316 shares worth $1.09M. The position accounts for 0.16% of the portfolio, ranked #115.

Personal CFO Solutions first reported a position in TEVA in Q3 2024 and has held it in 6 quarters since. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Personal CFO Solutions held 32,316 shares of Teva Pharmaceuticals worth $1.09M as of Q2 2026.
  • Personal CFO Solutions bought 833 Teva Pharmaceuticals shares in Q2 2026, an estimated $27.7K.
  • Teva Pharmaceuticals made up 0.16% of Personal CFO Solutions's portfolio in Q2 2026, its #115 holding.
  • Personal CFO Solutions first reported a position in Teva Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Personal CFO Solutions's 13F filing for Q2 2026, filed 7 Aug 2026.